Drug discovery in the next decade: innovation needed ASAP

Hughes, 2010, 2009 FDA drug approvals, Nat. Rev. Drug Discov., 9, 89, 10.1038/nrd3101 Dorren Corbett, 2010, Drug approvals slipped in 2010, Wall Street J. Cavalla, 2010, Does R&D pay?, Drug Discov. Today, 15, 230, 10.1016/j.drudis.2009.11.002 Williams, 2011, Productivity shortfalls in drug discovery: contributions from the preclinical sciences?, J. Pharmacol. Exp. Ther., 336, 3, 10.1124/jpet.110.171751 Whitesides, 2011, Let's get practical, Nature, 469, 21, 10.1038/469021a Peters, 1999 Ratner, 2010, Crossing the line, Nat. Biotechnol., 28, 1232, 10.1038/nbt.1726 Terwiesch, 2009 DiMassi, 2003, The price of innovation: new estimates of drug development costs, J. Health Econ., 22, 151, 10.1016/S0167-6296(02)00126-1 DiMassi, 2011, Competitiveness in follow-on R&D: a race or imitation, Nat. Rev. Drug Discov., 10, 23, 10.1038/nrd3296 Hammer, 2011, Lessons learned from Sanofi-Aventis's phase III failure, Seeking-Alpha Galemmo, 2005, Memorial issue in honor of Dr. Paul A.J. Janssen preface, J. Med. Chem., 48, 1686, 10.1021/jm040193r Nicolaou, 2000, The art and science of total synthesis at the dawn of the twenty-first century, Angew. Chem. Int. Ed., 39, 44, 10.1002/(SICI)1521-3773(20000103)39:1<44::AID-ANIE44>3.0.CO;2-L Driggers, 2008, The exploration of macrocycles for drug discovery: an underexploited structural class, Nat. Rev. Drug Discov., 7, 608, 10.1038/nrd2590 Clark, 2009, Design, synthesis and selection of DNA-encoded small-molecule libraries, Nat. Chem. Biol., 5, 647, 10.1038/nchembio.211 Noyori, 2009, Synthesizing our future, Nat. Chem., 1, 5, 10.1038/nchem.143 Teague, 1999, The design of leadlike combinatorial libraries, Angew. Chem. Int. Ed., 38, 3743, 10.1002/(SICI)1521-3773(19991216)38:24<3743::AID-ANIE3743>3.0.CO;2-U Festel, 2011, Outsourcing chemical synthesis in the drug discovery process drug, Drug Discov. Today, 16, 237, 10.1016/j.drudis.2011.01.002 Lipinski, 2000, Drug-like properties and the causes of poor solubility and poor permeability, J. Pharmacol. Toxicol. Methods, 44, 235, 10.1016/S1056-8719(00)00107-6 Leeson, 2007, The influence of drug-like concepts on decision-making in medicinal chemistry, Nat. Rev. Drug Discov., 6, 881, 10.1038/nrd2445 Johnson, 2009, Using the golden triangle to optimize clearance and oral absorption, Bioorg. Med. Chem. Lett., 19, 5560, 10.1016/j.bmcl.2009.08.045 Alelyunas, 2010, Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate, Bioorg. Med. Chem. Lett., 20, 7312, 10.1016/j.bmcl.2010.10.068 Milletti, 2010, Predicting polypharmacology by binding site similarity: from kinases to the protein universe, J. Chem. Inf. Model., 50, 1418, 10.1021/ci1001263 Lounkine, 2010, SARANEA: a freely available program to mine structure–activity and structure–selectivity relationship information in compound data sets, J. Chem. Inf. Model., 50, 68, 10.1021/ci900416a Agrafiotis, 2007, SAR Maps: a new visualization technique for medicinal chemists, J. Med. Chem., 50, 5926, 10.1021/jm070845m Michino, 2009, Community-wide assessment of GPCR structure modeling and ligand docking: GPCR Dock 2008 participants, Nat. Rev. Drug Discov., 8, 455, 10.1038/nrd2877 Wassermann, 2010, Activity landscape representations for SAR analysis, J. Med. Chem., 53, 8209, 10.1021/jm100933w Gardner, 2004, Drugs as materials: valuing physical form in drug discovery, Nat. Rev. Drug Discov., 3, 926, 10.1038/nrd1550 Connelly, P.R. et al. (2010) The integrated local CMC service provider: toward a deep economy of pharmaceuticals. Pharmaceut. Outsourcing 3091 Inglese, 2009, High throughput screening techniques: applications in chemical biology Wagner, 2009, Connecting synthetic chemistry decisions to cell and genome biology using small-molecule phenotypic screening, Curr. Opin. Chem. Biol., 13, 539, 10.1016/j.cbpa.2009.09.018 Terstappen, 2007, Target deconvolution strategies in drug discovery, Nat. Rev. Drug Discov., 6, 891, 10.1038/nrd2410 Raddatz, 2007, Allosteric approaches to the targeting of G-protein-coupled receptors for novel drug discovery: a critical assessment, Biochem. Pharmacol., 74, 383, 10.1016/j.bcp.2007.05.007 Conn, 2009, Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders, Nat. Rev. Drug Discov., 8, 41, 10.1038/nrd2760 Leach, 2007, Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology, Trends Pharmacol. Sci., 28, 382, 10.1016/j.tips.2007.06.004 May, 2007, Allosteric modulation of G protein-coupled receptors, Annu. Rev. Pharmacol. Toxicol., 47, 1, 10.1146/annurev.pharmtox.47.120505.105159 Kenakin, 2007, Allosteric agonist modulators, J. Recept. Signal Transduct. Res., 27, 247, 10.1080/10799890701509000 Kenakin, 2004, G-protein coupled receptors as allosteric machines, Receptors Channels, 10, 51, 10.1080/10606820490464316 Kenakin, 2005, New concepts in drug discovery: collateral efficacy and permissive antagonism, Nat. Rev. Drug Discov., 4, 919, 10.1038/nrd1875 Horrigan, 2002, Coupling between voltage sensor activation, Ca2+ binding and channel opening in large conductance (BK) potassium channels, J. Gen. Physiol., 120, 267, 10.1085/jgp.20028605 Horrigan, 1999, Allosteric voltage gating of potassium channels. I. Mslo ionic currents in the absence of Ca2+, J. Gen. Physiol., 114, 277, 10.1085/jgp.114.2.277 Monod, 1965, On the nature of allosteric transitions: a plausible model, J. Mol. Biol., 12, 88, 10.1016/S0022-2836(65)80285-6 Klepeis, 2009, Long-timescale molecular dynamics simulations of protein structure and function, Curr. Opin. Struct. Biol., 19, 120, 10.1016/j.sbi.2009.03.004 Korzhnev, 2008, Probing invisible, low-populated states of protein molecules by relaxation dispersion NMR spectroscopy: an application of protein folding, Acc. Chem. Res., 41, 442, 10.1021/ar700189y Henzler-Wildman, 2007, Dynamic personalities of proteins, Nature, 450, 964, 10.1038/nature06522 Selkoe, 2003, Folding proteins in fatal ways, Nature, 426, 900, 10.1038/nature02264 Chiti, 2006, Protein misfolding, functional amyloid, and human disease, Annu. Rev. Biochem., 75, 333, 10.1146/annurev.biochem.75.101304.123901 Wells, 2007, Reaching for high-hanging fruit in drug discovery at protein–protein interfaces, Nature, 450, 1001, 10.1038/nature06526 Ebert, 2010, Human stem cells and drug screening: opportunities and challenges, Nat. Rev. Drug Discov., 9, 367, 10.1038/nrd3000 Chudnovsky, 2005, Use of human tissue to assess the oncogenic activity of melanoma-associated mutations, Nat. Genet., 37, 745, 10.1038/ng1586 Rowland, 2010, Physiologically-based pharmacokinetics in drug development and regulatory science, Annu. Rev. Pharmacol. Toxicol., 51, 45, 10.1146/annurev-pharmtox-010510-100540 1999 Garcia-Calvo, 2005, The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1), Proc. Natl. Acad. Sci. U. S. A., 102, 8132, 10.1073/pnas.0500269102 Kloner, 2001, Effects of sildenafil in patients with erectile dysfunction taking antihypertensive therapy, Am. J. Hypertens., 14, 70, 10.1016/S0895-7061(00)01177-8 Zambrowicz, 2003, Knockouts model the 100 best-selling drugs: will they model the next 100?, Nat. Rev. Drug Discov., 2, 38, 10.1038/nrd987 Goodsaid, 2010, Voluntary exploratory data submission to the FDA and the EMA: experience and impact, Nat. Rev. Drug Discov., 9, 435, 10.1038/nrd3116 Terzic, 2010, Channelopathies: decoding disease pathogenesis, Sci. Translat. Med., 2, 10.1126/scitranslmed.3001433 Strom, 2010, Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity, Hepatocytes: Methods Protoc., 640, 491, 10.1007/978-1-60761-688-7_27 Legrand, 2009, Humanized mice for modeling human infectious disease: challenges, progress, and outlook, Cell Host Microbe, 6, 5, 10.1016/j.chom.2009.06.006 Van Duyne, 2009, The utilization of humanized mouse models for the study of human retroviral infections, Retrovirology, 6, 76, 10.1186/1742-4690-6-76 Zhang, 2009, Mouse models with human immunity and their application in biomedical research, J. Cell. Mol. Med., 13, 1043, 10.1111/j.1582-4934.2008.00347.x Cheung, 2008, Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment, J. Pharmacol. Exp. Therapeut., 327, 288, 10.1124/jpet.108.141242 Macchiarini, 2005, Humanized mice: are we there yet?, J. Exp. Med., 202, 1307, 10.1084/jem.20051547 Hopkins, 2008, Network pharmacology: the next paradigm in drug discovery, Nat. Chem. Biol., 4, 682, 10.1038/nchembio.118 Shukla, 2010, The future of toxicity testing: a focus on in vitro methods using a quantitative high-throughput screening platform, Drug Discov. Today, 15, 997, 10.1016/j.drudis.2010.07.007 Prestwich, 2007, Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery, Acc. Chem. Res., 41, 139, 10.1021/ar7000827 Hughes, 2008, Drug properties associated with in vivo toxicological outcomes, Bioorg. Med. Chem. Lett., 18, 4872, 10.1016/j.bmcl.2008.07.071 Munos, 2009, Lessons from 60 years of pharmaceutical innovation, Nat. Rev. Drug Discov., 8, 959, 10.1038/nrd2961 Paul, 2010, How to improve R&D productivity: the pharmaceutical industry's grand challenge, Nat. Rev. Drug Discov., 9, 203, 10.1038/nrd3078 Agarwal, 2009, Can literature analysis identify innovation drivers in drug discovery?, Nat. Rev. Drug Discov., 8, 865, 10.1038/nrd2973 Hoffmann, 2010, The future of discovery chemistry: quo vadis? Academic to industrial: the maturation of medicinal chemistry to chemical biology, Drug Discov. Today, 15, 260, 10.1016/j.drudis.2010.02.002 Root-Bernstein, 1989 Perola, 2010, An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs, J. Med. Chem., 53, 2986, 10.1021/jm100118x Osono, 2008 Hua, 2006, Integration TRIZ with problem-solving tools: a literature review from 1995–2006, Int. J. Bus. Innovat. Res., 111, 10.1504/IJBIR.2006.011091 Hamm, 2008 Chadwick, 2010, Overcoming psychological barriers to good discovery decisions, Drug Discov. Today, 15, 561, 10.1016/j.drudis.2010.05.007 Ecemis, 2008, A drug candidate design environment using evolutionary computation, IEEE Trans. Evol. Comput., 12, 591, 10.1109/TEVC.2007.913131 Bonabeau, 2003 Jensen, 2008, Aliskiren: the first renin inhibitor for clinical treatment, Nat. Rev. Drug Discov., 7, 399, 10.1038/nrd2550 Giacomini, 2010, Membrane transporters in drug development, Nat. Rev. Drug Discov., 9, 215, 10.1038/nrd3028 Chin, 2006, Drug discovery from natural sources, AAPS J., 8, E239, 10.1007/BF02854894 Haefner, 2003, Drugs from the deep: marine natural products as drug candidates, Drug Discov. Today, 8, 536, 10.1016/S1359-6446(03)02713-2 Bade, 2010, Characteristics of known drug space; natural products, their derivatives and synthetic drugs, Eur. J. Med. Chem., 45, 5646, 10.1016/j.ejmech.2010.09.018 Koehn, 2005, The evolving role of natural products in drug discovery, Nat. Rev. Drug Discov., 4, 206, 10.1038/nrd1657 Potashman, 2009, Covalent modifiers: an orthogonal approach in drug design, J. Med. Chem., 52, 1231, 10.1021/jm8008597 Clader, 2004, The discovery of ezetimibe: a view from outside the receptor, J. Med. Chem., 47, 1, 10.1021/jm030283g Adams, 1998, Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids, Bioorg. Med. Chem. Lett., 8, 333, 10.1016/S0960-894X(98)00029-8 Perni, 2006, Preclinical profile of Telaprevir, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease, Antimicrob. Agents Chemother., 50, 899, 10.1128/AAC.50.3.899-909.2006 Maltais, 2009, In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated Telaprevir versus Telaprevir in rats, J. Med. Chem., 52, 7993, 10.1021/jm901023f Badaru, 2006, Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty, J. Clin. Endocrinol. Metab., 91, 1862, 10.1210/jc.2005-1500 Steenbergen, 2005, Daptomycin: a lipopeptide antibiotic for the treatment of serious gram-positive infections, J. Antimicrob. Chemother., 55, 283, 10.1093/jac/dkh546 Walsh, 2004, Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia, N. Engl. J. Med., 351, 1391, 10.1056/NEJMoa040446 Vézina, 1975, Rapamycin (AY-22,989), a new antifungal antibiotic, J. Antibiot., 28, 721, 10.7164/antibiotics.28.721 Rubio-Viqueira, 2006, Targeting mTOR for cancer treatment, Curr. Opin. Investig. Drugs, 7, 501 Singhal, 1999, Antitumor activity of thalidomide in refractory multiple myeloma, N. Engl. J. Med., 341, 1565, 10.1056/NEJM199911183412102 Lepor, 1991, The efficacy and safety of terazosin in the treatment of BPH, Prostate, 18, 345, 10.1002/pros.2990180408 Itoh, 1984, Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut, Antimicrob. Agents Chemother., 26, 863, 10.1128/AAC.26.6.863 Brown, 1973, Motilin, a gastric motor activity stimulating polypeptide: the complete amino acid sequence, Can. J. Biochem., 51, 533, 10.1139/o73-066 Feighner, 1999, Receptor for motilin identified in the human gastrointestinal system, Science, 284, 2184, 10.1126/science.284.5423.2184 Feighner, S.D. et al. (1999) Cloning and identification of the human motilin receptor isoforms. PCT Int. Appl. WO 9964436 A1 19991216 Gladwell, 2008 Kim, 2005 Knutsen, 2011, Drug discovery management, small is still beautiful: why a number of companies get it wrong, Drug Discov. Today, 10.1016/j.drudis.2011.04.002 Lehrer, J. (2010) Accept defeat: the neuroscience of screwing up. Wired Mag. http://www.wired.com/magazine/2009/12/fail_accept_defeat/ Clark, 2004, Outsourcing lead optimisation – the quiet revolution, Drug Discov. Today, 9, 492, 10.1016/S1359-6446(04)03102-2